RxDoctor Payments Data

Kiran Reddy, MD

Internal Medicine · Fresno, CANPI 1588778435

Payments from drug & device makers

$1,925in general payments, 2019–2025

Across 44 payments — averaging $43.75 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abiomed$512
  • Medtronic$324
  • Abbott$180
  • Gilead$150
  • Shockwave Medical, Inc$142
  • Novo Nordisk$140
  • plus $477 from 12 others

What the payments were for

  • Food & beverage$1,925100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,925 in reported general payments places this provider in the 80th percentile of 13,581 internal medicine providers in California.

See all internal medicine providers in California

Medicare billing

Part B allowed, 2024
$45,277
Medicare patients
181
Services billed
524

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide137$186,363
JardianceEmpagliflozin70$101,600
RybelsusSemaglutide15$42,240
MounjaroTirzepatide28$35,409
EliquisApixaban33$35,097
Tresiba Flextouch U-200Insulin Degludec29$32,573
Trelegy ElliptaFluticasone/Umeclidin/Vilanter31$31,311
TradjentaLinagliptin23$27,830
MyrbetriqMirabegron17$16,802
LinzessLinaclotide20$16,613
JanuviaSitagliptin Phosphate15$13,894
Repatha SureclickEvolocumab11$11,529
Repatha SyringeEvolocumab11$7,243
Dexlansoprazole DrDexlansoprazole14$6,500
Fiasp FlextouchInsulin Aspart (Niacinamide)12$5,699

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$140$228,603152 claims
Lilly USA, LLCMounjaro$49$35,40928 claims
AbbVieLinzess$26$16,61320 claims
MerckJanuvia$50$13,89415 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 13,581 internal medicine providers in California.

Other internal medicine in Fresno

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →